-

SHAREHOLDER ALERT: Robbins LLP Announces That Ontrak, Inc. (OTRK) is Being Sued for Misleading Shareholders

SAN DIEGO & SANTA MONICA, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Ontrak, Inc. (NASDAQ: OTRK) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between November 5, 2020 and February 26, 2021. Ontrak is a healthcare company that offers a Predict-Recommend-Engage platform that organizes and automates healthcare data integration and analytics. Ontrak programs provide healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions.

If you suffered a loss due to Ontrak Inc.'s misconduct, click here.

Ontrak, Inc. (OTRK) Misled Investors About the Impact Losing its Largest Customer Would Have on its Financial Results

According to the complaint, Ontrak failed to disclose that: (1) its largest customer evaluated the Company on a provider basis, valuing Ontrak’s performance based on achieving the lowest cost per medical visit rather than clinical outcomes or medical cost savings; (2) as a result, Ontrak’s largest customer did not find the Company’s program to be effective and was reasonably likely to terminate its contract with Ontrak; and (3) because this customer accounted for a significant portion of the Company's revenue, the loss of the customer would have an outsized impact on Ontrak's financial results.

On March 1, 2021, Ontrak announced its preliminary financial results for fourth quarter and full year 2020 and shared that its largest customer had terminated its contract with Ontrak effective June 26, 2021. Apparently, "the customer evaluated [Ontrak's] performance based on [its] ability to achieve the lowest possible cost per medical visit, and not on [its] clinical outcomes data or medical cost savings, which were meaningful and significant." Further, "the coaching model which Ontrak has pioneered for over a decade was seen by the customer as less relevant to their performance metrics." On this news, Ontrak's share price fell $27.32, or more than 46% to close at $31.62 per share on March 2, 2021.

If you purchased shares of Ontrak, Inc. (OTRK) between November 5, 2020 and February 26, 2021, you have until May 3, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Ontrak, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Alert: Robbins LLP Informs Investors of the Wise Group plc Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle compli...

Shareholder Alert - Robbins LLP Informs Investors of the Bloom Energy Corporation Class Action Lawsuit 

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Bloom Energy Corporation (NYSE: BE) securities between February 27, 2025 and July 8, 2026 (the "Class Period").Bloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation in the United States and internationally. Scandium is a rare earth metal used as a dopant to st...
Back to Newsroom